News
LVCLF
0.0035
NaN%
--
Algorae Discloses Director’s Indirect Acquisition of Shares
TipRanks · 3d ago
Algorae Pharmaceuticals Reports Director Interest Change
TipRanks · 11/11 08:02
Algorae Pharmaceuticals Receives Strong AGM Shareholder Support
TipRanks · 11/05 03:07
Algorae Expands Pharmaceutical Portfolio and Validates AI Drug Discovery Platform
TipRanks · 11/04 23:07
Algorae Pharma Issues Non-Deal Investor Presentation with Comprehensive Disclaimers
TipRanks · 10/29 22:57
Algorae Pharmaceuticals secures NSW Health supply role and advances AI drug‑discovery platform
TipRanks · 10/29 22:56
Algorae Pharmaceuticals Tightens Governance With Updated Securities Trading Policy
TipRanks · 10/28 07:53
AlgoraeRx inks Umedica supply deals to deepen Australian medicines portfolio
TipRanks · 10/19 07:20
Algorae Pharmaceuticals Sets Date and Process for 2026 AGM
TipRanks · 10/07 05:57
Algorae Pharmaceuticals Sets November Date for AGM Amid AI-Driven Growth Strategy
TipRanks · 09/10 08:50
Algorae Pharmaceuticals Lapses 10 Million Performance Rights After Unmet Conditions
TipRanks · 09/02 07:28
Algorae Pharmaceuticals Losses Deepen as Commercial Operations Expand
TipRanks · 08/31 06:18
Algorae bolsters board with Nasdaq pharmaceutical chairman Troy Valentine
TipRanks · 07/14 23:17
Algorae Pharmaceuticals Issues 2 Million New Shares Under Cleansing Notice
TipRanks · 07/06 07:13
Algorae Pharmaceuticals Seeks ASX Quotation for 2 Million New Shares
TipRanks · 07/06 07:12
AlgoraeOS v2 Wins Independent Validation for Cancer Drug Synergy Predictions
TipRanks · 07/02 23:17
Algorae Wins NSW Health Hospital Supply Deal in Key Commercial Milestone
TipRanks · 07/01 02:06
Algorae Pharmaceuticals appoints joint company secretaries as it advances AI-driven drug strategy
TipRanks · 06/30 06:38
Algorae Joins Sovereign AI Infrastructure as Healthcare Launch Partner
TipRanks · 06/28 23:43
Algorae Pharmaceuticals switches auditors to address independence concerns
TipRanks · 06/24 08:38
More
Webull provides a variety of real-time LVCLF stock news. You can receive the latest news about Algorae Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About LVCLF
Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled pharmaceutical development company. The Company’s proprietary AI platform, Algorae Operating System (AlgoraeOS), is an AI platform that leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. Its other drug candidates include AI-116, AI-168, NTCELL. AI-116 is a combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease. AI-168 is a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient, which is conceptualized to be a potential treatment for cardiovascular disease, including hypertension. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.